Actively Recruiting
Evaluating Personalized Medicine Recommendations for Optimal Drug Therapy in Adult Cancer Patients
Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2025-07-09
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how personalized medicine clinic recommendations affect drug levels, effectiveness, and side effects of commonly used antidepressants, pain medications, and antiemetics in adult cancer patients. The study focuses on the impact of genetic differences and drug interactions on treatment with these medications. It aims to see if these personalized recommendations improve drug response and reduce side effects over six months. The study involves three groups of cancer patients taking specific medications: antidepressants (citalopram, escitalopram, venlafaxine, desvenlafaxine), opioid pain medications (codeine, oxycodone, hydrocodone, tramadol), and the antiemetic ondansetron. Patients will attend a personalized medicine clinic for genotype-guided treatment advice considering drug interactions. They will have visits at screening, then 0.5, 4 (virtual), and 7 months after, with blood samples and clinical data collected. Participants will complete surveys measuring symptoms like depression, pain, nausea, and medication side effects at each visit. Drug levels and treatment effectiveness will be assessed at baseline and six months after recommendations. This will help researchers understand how genetics and drug interactions affect medication response in cancer care. The total study participation lasts about seven months with ongoing monitoring of symptoms and drug exposure.
CONDITIONS
Brief Title
Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Prescribed a chemotherapy medication
- Currently taking one or more of the following medications: citalopram, escitalopram, venlafaxine, desvenlafaxine, codeine, oxycodone, hydrocodone, tramadol, or ondansetron
You will not qualify if you...
- Unable to complete study surveys in English, even with assistance
- Receiving palliative care
- Taking antidepressants for reasons other than depression or anxiety (applies to antidepressant group)
- Having major depressive disorder diagnosed before cancer diagnosis (applies to antidepressant group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 7 months
Participants attend three follow-up visits where clinical information and blood samples are collected, and they complete surveys to evaluate treatment effectiveness.
1 baseline visit and 2 follow-up visits (1 virtual, 2 in-person)
Trial Site Locations
Total: 1 location
1
Lawson Health Research Institute
London, Ontario, Canada, N6C 2R5
Actively Recruiting
Research Team
R
Richard Kim, MD
S
Samantha Medwid, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here